Insulin aspart (Fiasp) vs Insulin Lispro

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (Fiasp)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

Insulin Lispro · Humalog

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01474538 · Phase 3 · completed

The study randomized 122 participants to receive both insulin lispro and insulin aspart in crossover order, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint, HbA1c after 16 weeks, met the prespecified non-inferiority criterion for lispro versus aspart, with the upper confidence limit below the 0.4% margin.

Next expected readout: December 2026 · NCT06251635 (registry estimate)

Reported efficacy

Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Glycosylated Hemoglobin A1C (HbA1c) at Endpoint (After 16 weeks of each treatment (Periods1 and 2)): Insulin Lispro 7.5 percentage of glycosylated hemoglobin (Standard Error 0.12) | Insulin Aspart 7.4 percentage of glycosylated hemoglobin (Standard Error 0.12) (met)

Result source: NCT01474538

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (Fiasp)Insulin Lispro
HbA1c, change6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705
Body weight, change (kg)1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534
HbA1c below 7%—Not reported32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
Fasting plasma glucose, change0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227
3-point MACE (% with event)—Not reported—Not posted · NCT00551356

HbA1c, change

Insulin aspart (Fiasp)
6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
Insulin Lispro
-1.2% vs -1.1%vs Insulin Glargine1.5 mg · wk 26 · n 138NCT01621178
20 other results
  • -1.6% vs -1.4% 1.5 mg · wk 26 · n 273 · Phase 3 · primary NCT01191268
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.6% vs -1.4% 0.75 mg · wk 26 · n 275 · Phase 3 · primary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 345 · Phase 3 · primary NCT02229227
  • -1.7% vs -1.4% wk 26 · n 684 · Phase 3 · primary NCT01468987
  • -1.2% vs -1.3% wk 24 · n 148 · Phase 3 · primary NCT00666718
  • -1.5% vs -1.2% 1.5 mg · wk 52 · n 273 · Phase 3 · secondary NCT01191268
  • -1.4% vs -1.2% 0.75 mg · wk 52 · n 275 · Phase 3 · secondary NCT01191268
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.0% vs -1.1% wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1.3% wk 24 · n 179 · Phase 3 · secondary NCT00666718
  • -1.0% vs -1.1% wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -0.9% vs -1.0% wk 12 · n 179 · Phase 3 · secondary NCT00666718
  • -0.9% vs -1.0% wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -0.7% vs -0.6% wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6% vs -0.5% wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1% vs -0.8% wk 16 · n 131 · Phase 4 · secondary NCT00393705

Body weight, change (kg)

Insulin aspart (Fiasp)
1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005
Insulin Lispro
-2.8 vs 1.1vs Insulin Glargine1.5 mg · wk 26 · n 140NCT01621178
15 other results
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -2.0 vs 2.1 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.7 vs 1.5 wk 10 · n 402 · Phase 3 · secondary NCT02229227
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • 1.0 vs 1.2 wk 24 · n 187 · Phase 3 · secondary NCT00666718
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • -1.9 vs 2.4 wk 26 · n 349 · Phase 3 · secondary NCT02229227
  • -1.9 vs 2.4 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • 1.3 vs 2.2 wk 26 · n 682 · Phase 3 · secondary NCT01468987
  • -0.9 vs 0.8 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -0.6 vs 0.7 wk 4 · n 402 · Phase 3 · secondary NCT02229227
  • 0.3 vs 0.9 wk 16 · n 116 · Phase 3 · secondary NCT01474538
  • 1.3 vs 0.4 wk 16 · n 126 · Phase 4 · secondary NCT00393705
  • 2.6 vs 2.7 wk 48 · n 138 · Phase 4 · secondary NCT00664534

HbA1c below 7%

Insulin aspart (Fiasp)
—Not reported
Insulin Lispro
32.9% vs 29.1%vs Insulin Glargine1.5 mg · wk 52 · n 152NCT01621178
3 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178

Fasting plasma glucose, change

Insulin aspart (Fiasp)
0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005
Insulin Lispro
-2.0 vs -1.5vs Insulin Lispro + Insulin Glarginewk 26 · n 345NCT02229227
4 other results
  • -2.0 vs -1.5 wk 26 · n 402 · Phase 3 · secondary NCT02229227
  • -1.8 vs -1.2 wk 18 · n 402 · Phase 3 · secondary NCT02229227
  • -1.1 vs -0.9 wk 5 · n 402 · Phase 3 · secondary NCT02229227
  • -1.3 vs -0.8 wk 4 · n 402 · Phase 3 · secondary NCT02229227

3-point MACE (% with event)

Insulin aspart (Fiasp)
—Not reported
Insulin Lispro
—Not posted · NCT00551356
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Insulin aspart (Fiasp): 6 of 6 rows · Insulin Lispro: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin aspart (Fiasp)
Rows use multiple source trials
Insulin Lispro
Rows use multiple source trials
BMI
absolute change · kg
0.43 vs 0.4 NovoRapid kg @ 16wka,b,c
NCT03268005 · Phase 3 · registry result, not featured evidence
0.09 vs 1.33 Insulin Glargine kg @ 52wk1.5 mgd,a,b,c
NCT01191268 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.57 vs 1.33 Insulin Glargine kg @ 52wk0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
event count · % of participants
49.6% (n=546) vs 51.7% (n=545) NovoRapid @ 16wk*e,a,b,f
Yes
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 271 Participants as posted
60.7% (n=402) vs 61.9% (n=412) Insulin Lispro + Insulin Glargine @ 26wk*d,e,a,b,f
NCT02229227 · Phase 3 · registry result, not featured evidence · combination · converted to % from 244 Participants as posted
show 1 more dose
60.7% (n=402) vs 61.9% (n=412) Insulin Lispro + Insulin Glargine @ 26wk*
NCT02229227 · Phase 3 · registry result, not featured evidence · combination · converted to % from 244 Participants as posted
Dropout rate
12.8%g
NCT01819129 · Phase 3
show 2 more results
7.8%
NCT01850615 · Phase 3 · combination
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
—h
NCT01474538 · Phase 3
show 18 more results
19.3%
NCT00664534 · Phase 4 · registry result, not featured evidence
15.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
12.7%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
10.3%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
19.7%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
18.8%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
9.6%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
11.1%
NCT05893797 · Phase na · registry result, not featured evidence
Discontinued due to AEs
0.3%g
NCT01819129 · Phase 3
show 2 more results
1.7%
NCT01850615 · Phase 3 · combination
—
NCT03268005 · Phase 3 · registry result, not featured evidence
—h
NCT01474538 · Phase 3
show 18 more results
1.8%
NCT00664534 · Phase 4 · registry result, not featured evidence
0%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
3.5%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
—1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
—0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
1.7%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
7.1%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.4%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
—Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0.5%ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
—Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
—Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
—Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
—Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
—
NCT02197520 · Phase 1 · registry result, not featured evidence
2.8%
NCT05893797 · Phase na · registry result, not featured evidence
Serious AEs
4.4%g
NCT01819129 · Phase 3
show 2 more results
5.2%
NCT01850615 · Phase 3 · combination
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
12.7%h
NCT01474538 · Phase 3
show 18 more results
4.1%
NCT00664534 · Phase 4 · registry result, not featured evidence
2.2%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.8%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
21.4%1.5 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
25.3%0.75 mg
NCT01621178 · Phase 3 · registry result, not featured evidence
11.4%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
9.2%1.5 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
15.7%0.75 mg
NCT01191268 · Phase 3 · registry result, not featured evidence
4.8%Glargine/Lispro
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
—ILPS
NCT00666718 · Phase 3 · registry result, not featured evidence
7.5%Lispro/Metformin
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
0%Insulin Lispro (Lispro-PH20 Cohort
NCT01194258 · Phase 2 · registry result, not featured evidence
0%Lispro-PH20
NCT01194258 · Phase 2 · registry result, not featured evidence
4.5%Humalog + rHuPH20
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
0%Humalog Alone
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
0%
NCT02197520 · Phase 1 · registry result, not featured evidence
8.3%
NCT05893797 · Phase na · registry result, not featured evidence
Most frequent reported AEs
g
urinary tract infection 5.9%
nasopharyngitis 5%
upper respiratory tract infection 4.7%
NCT01819129 · Phase 3
show 2 more results
diarrhoea 1.7%
NCT01850615 · Phase 3 · combination
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
h
nasopharyngitis 4.2%
nausea 4.2%
fatigue 3.4%
NCT01474538 · Phase 3
show 17 more results
pyrexia 3.6%
neuropathy peripheral 3%
diarrhoea 2.4%
NCT00664534 · Phase 4 · registry result, not featured evidence
nasopharyngitis 4.3%
bronchitis 2.2%
arthralgia 1.4%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 9.3%
diarrhoea 7.8%
viral upper respiratory tract infection 6.3%
NCT02229227 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3 · registry result, not featured evidence
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.1%
upper respiratory tract infection 4.2%
diarrhoea 3.5%
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
nausea 25.8%
diarrhea 14.9%
vomiting 11.9%
NCT01191268 · Phase 3 · registry result, not featured evidence
0.75 mg
nausea 17.7%
diarrhea 11.6%
vomiting 10.6%
NCT01191268 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.4%
headache 5.9%
diarrhoea 4.3%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 5.3%
headache 4.8%
viral infection 3.7%
NCT00666718 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
headache 3.4%
influenza 3.4%
NCT01194258 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 11.9%
diarrhoea 8.5%
nasopharyngitis 5.1%
NCT01194258 · Phase 2 · registry result, not featured evidence
abdominal pain 4.5%
diarrhoea 4.5%
injection site pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · combination
headache 13.6%
nausea 9.1%
abdominal pain 4.5%
NCT00916357 · Phase 2 · registry result, not featured evidence · monotherapy
catheter site related reaction 12.5%
upper respiratory tract infection 12.5%
urinary tract infection 12.5%
NCT02197520 · Phase 1 · registry result, not featured evidence
covid-19 8.3%
bronchitis 5.6%
dermatitis allergic 5.6%
NCT05893797 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 52 weeks versus 16 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eThe reported result categories differ.
  6. fAssessment timepoints differ: 26 weeks versus 16 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin aspart (Fiasp)

PPG Excursion 4.55 vs 4.9 NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT01819129 · Phase 3
show 1 more result
-0.43 vs 0.08 NovoRapid mmol/L @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7 Without Severe Hypoglycemia 48.5% (n=546) vs 51% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 265 Participants as posted
SMBG Daily Average -0.56 vs -0.5 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
SMPG-mean Post Prandial Increment -0.48 vs -0.23 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
All meals
NCT03268005 · Phase 3 · registry result, not featured evidence
Postprandial Glucose Leq 7.8 34.1% (n=546) vs 35.2% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 186 Participants as posted
Postprandial Glucose Leq 7.8 mmol/L Without Severe Hypoglycemia 33.3% (n=546) vs 34.9% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 182 Participants as posted

Insulin Lispro

HbA1c 7.5% (n=112) vs 7.4% (n=111) Insulin Aspart @ 16wk
absolute value · percentage points
NCT01474538 · Phase 3
show 6 more results
7.4% (n=108) vs 7.55% (n=98) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.62% (n=158) vs 7.57% (n=163) Glargine @ 16wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.46% (n=158) vs 7.43% (n=163) Glargine @ 32wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.33% (n=158) vs 7.4% (n=163) Glargine @ 48wk
NCT00664534 · Phase 4 · registry result, not featured evidence
7.71% (n=131) vs 7.84% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
6.76% (n=684) vs 6.97% (n=672) Insulin Glargine + Insulin Lispro @ 26wk
NCT01468987 · Phase 3 · registry result, not featured evidence · combination
HbA1c Less Than 7% 30.3% (n=158) vs 24.2% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=7.0% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 18.7% (n=158) vs 14.6% (n=163) Glargine @ 16wk
responder rate · % of participants
Week 16 HbA1c <=6.5% (n=157, n=155)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 37.6% (n=158) vs 32.1% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=7.0% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 20.6% (n=158) vs 19% (n=163) Glargine @ 32wk
responder rate · % of participants
Week 32 HbA1c <=6.5% (n=137, n=141)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 48.2% (n=158) vs 36.2% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=7.0% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 24.8% (n=158) vs 18.5% (n=163) Glargine @ 48wk
responder rate · % of participants
Week 48 HbA1c <=6.5% (n=130, n=137)
NCT00664534 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7% 21.4% (n=131) vs 18.5% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c <7%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
A1C Less Than 6 5 11.5% (n=131) vs 6.7% (n=135) Insulin Biphasic Aspart 30/70 or Insulin Lispro LM @ 16wk
responder rate · % of participants
HbA1c ≤6.5%
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PP 2 h Glucose mg/dL 163.4 vs 178.2 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h Excursion mg/dL 17 vs 36.1 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
NCT00393705 · Phase 4 · registry result, not featured evidence · combination
Fasting Plasma Glucose mg/dL 161.1 vs 153.9 Insulin Biphasic Aspart 30/70 or Insulin Lispro LM mg @ 16wk
absolute value · mg
Fasting
NCT00393705 · Phase 4 · registry result, not featured evidence · combination

+ 45 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · Insulin Lispro's landscape